To make an appointment, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment online
As a leader in cancer research, Karmanos is able to offer patients access to innovative treatments and clinical trials that are often times not available anywhere else.
To offer hope and longer life to patients with all types of cancer, Karmanos offers the latest types of therapy through our clinical trials program. Through clinical trials, we are creating new knowledge about how therapies fight cancer and provide national leadership in testing these new therapies.
We understand that cancer is a complex disease that demands complex care. We provide each patient with a dynamic, carefully constructed treatment plan focused on their specific cancer and their unique needs.
We listen to you to design a plan that provides you with respect, compassionate care and is responsive to your emotional and practical concerns.
Phase 1 (Dose-escalation and Dose-expansion)
Primary Objectives:
Part A: Dose-escalation:
Part B: Dose-expansion:
Secondary Objectives (Parts A and B):
For inclusion in the study, all of the following inclusion criteria must be fulfilled.
For Part B Cohort MR2 only:
For Part B Cohort CR1 only:
For Part B Cohort CR2 only:
Subjects are not eligible for this study if they fulfill any of the following exclusion criteria:
Palliative radiotherapy is permitted with a safety break, the length of which is at the discretion of the Investigator. Radiotherapy directed at sites of disease assessment is also permitted at the discretion of the Investigator and exclusion of the radiated site for disease assessments.
For Part B Cohorts CR1 and CR2: toxicity from ongoing chemotherapy that is reversible and expected to resolve (based on the discretion of the treating physician) by the time of LD chemotherapy is not necessarily exclusionary.